tirzepatide autoimmune disease associated encephalitis: A case report The Exhilirating Movement From Treatment

Yes, HSA approved tirzepatide injection for weight management in June 2025 for adults who meet specific body mass index and weight related comorbidity criteria

doi: 10.1371/journal.pone.0063641

According to the UK product information, nausea and diarrhoea are very common side effects of Ozempic, while vomiting, constipation, abdominal pain, and abdominal distension (bloating) are common

This vitamin A derivative stimulates collagen production and accelerates cell turnover

A Few States Are Doing It Anyway

In December 2025, the FDA approved a daily pill version of Wegovy, giving needle-averse patients the first oral GLP-1 option cleared for obesity treatment